Dr. Yuan Xu, Vice President and Head of Biotherapeutics Development, Novartis, United States will be speaking on the above topic at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Dr Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit at Novartis, GNF/NIBR. Yuan joined Novartis in 2008. Previously, she held the following positions: 2008-2011: Novartis, Global Head and Vice President of Process Sciences & Production and Basel Site Head for Novartis Biologics. 2006-2008: Amgen, first as Global Head leading Corporate Process and Clinical Operations then as Global Head leading Global Operations Strategy. 2004-2006: Chiron/Novartis, as Senior Director of Global Regulatory Affairs, as well as Global Program Head. 2003-2004: GlaxoSmithKline, Senior Group Director of Worldwide Biopharm Development 1995-2003: Genentech, held roles of increasing responsibility in Process Sciences, including Head of Pilot Plant Operations. Dr Yuan has extensive scientific/technical expertise and development/regulatory experience with multiple successful biotech products: Activase, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Raptiva, Avastin, Lucentis, Bexxar, Bacaplemin, Proleukin, Epogen, Enbrel, Prolia and Ilaris. Dr Yuan performed Postdoc training in Molecular Virology and Gene Therapy from University of California at San Diego Medical School. Dr Yuan has a Ph.D. in Protein Biochemistry from the University of Maryland at College Park and a B.S. in Biochemistry and Molecular Biology from Nanjing University in China.